Levofloxacin

FDA

• Acute bacterial exacerbations of chronic bronchitis (ABECB)
• Acute bacterial sinusitis
• Uncomplicated urinary tract infections
• Note: use of levofloxacin for these indications should be avoided due to FDA warnings (black box warnings) regarding serious side effects and potentially permanent (tendinitis and tendon rupture, peripheral neuropathy and CNS side effects). FDA safety warning regarding Fluoroquinolone use
• Pneumonia: community-acquired pneumonia and nosocomial pneumonia
• Inhalational anthrax (post-exposure)
• Uncomplicated and complicated skin and soft tissue infections (not MRSA)
• Complicated urinary tract infections
• Acute pyelonephritis
• Bacterial conjunctivitis (Quixin 0.5% ophthalmic drops)
  • Treatment of corneal ulcer (1.5% ophthalmic solution)
• Chronic bacterial prostatitis

NON-FDA

• Treatment of M. tuberculosis, including MDR and XDR-TB (in combination with other agents)

• Treatment of MAI and other non-TB mycobacterial infections (in combination with other agents)
• Alternative therapy for treating S. pneumoniae and H. influenzae meningitis in patients with severe penicillin allergies.
• Bone and joint infections
• Intra-abdominal infections in combination with metronidazole
• H. pylori, in combination with other agents
• Prophylaxis in neutropenic patients